Relationship of P-cadherin expression to the expression of other tumour markers in patients with breast cancer
| Molecular phenotype | Studies (n) | Patients (n) | Model | Pooled OR (95% CI) | P value | Heterogeneity | |
| I2 (%) | P value | ||||||
| ER-positive | 15 | 4690 | Random | 0.33 (0.21 to 0.52) | <0.0001 | 92 | <0.00001 |
| PR-positive | 11 | 2666 | Random | 0.33 (0.22 to 0.49) | <0.00001 | 87 | <0.00001 |
| HER2-positive | 12 | 1092 | Random | 2.47 (1.93 to 3.16) | <0.00001 | 51 | 0.02 |
| Ki-67-positive | 6 | 2170 | Random | 2.65 (1.94 to 3.62) | <0.00001 | 66 | 0.01 |
| EGFR-positive | 4 | 397 | Random | 6.04 (4.05 to 9.03) | <0.00001 | 45 | 0.14 |
| CK5/6-positive | 6 | 699 | Random | 6.79 (4.53 to 10.20) | <0.00001 | 68 | 0.008 |
CK, cytokeratin; EGFR, epidermal growth factor receptor; ER, oestrogen receptor; HER2, human epidermal growth factor receptor-2; PR, progesterone receptor.